Rapid Micro Biosystems (NASDAQ:RPID) delivered a record-breaking performance in the final quarter of 2025, signaling a tipping point in the adoption of its automated quality control technology by the world's largest pharmaceutical companies.
The Lexington, Massachusetts-based firm reported total revenue of $11.3 million for the quarter ended Dec. 31, 2025, representing 37% growth year-over-year.
This momentum was driven by the placement of 16 Growth Direct systems in the quarter—a company record—bringing its cumulative global footprint to 190 systems.
For the full year, revenue climbed 20% to $33.6 million.
Despite the top-line success, the company recorded a net loss of $47.1 million for 2025, roughly flat compared to the previous year, as it continues to invest in scaling its commercial and manufacturing infrastructure.
The quarter was highlighted by a significant "second wave" order from Amgen, which is rolling out the Growth Direct platform across its global manufacturing network in North America, Europe, and Asia.
Adding to this momentum, Rapid Micro today announced a new multi-system follow-on order from Samsung Biologics, focusing on South Korean operations.